Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability.
infectious diseases
pharmacokinetic-pharmacodynamic
population analysis
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
23
01
2020
revised:
19
06
2020
accepted:
26
06
2020
pubmed:
8
7
2020
medline:
27
7
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
The population pharmacokinetics (PK) of anidulafungin in critically ill patients hospitalized in intensive care units (ICUs) was explored with the intention of evaluating and optimizing dosing regimens. A PK study was conducted in a cohort of 13 patients treated with anidulafungin using intensive sampling during multiple periods per patient and the high-performance liquid chromatography method for drug quantification. A population PK model was developed to describe the concentration-time course of anidulafungin and the inter-individual (IIV) and interoccasion variability (IOV) of the PK parameters. Model-based PK simulations have been performed to estimate the probability of target attainment (PTA), given the pharmacokinetic/pharmacodynamic target of free 24-hour area under the free drug concentration-time curve over minimum inhibitory concentration for several dosing regimens. A two-compartment PK model, with first-order elimination, best described the data with population clearance (CL) and central/peripheral volume of distribution (V1/V2) of 0.778 L/h and 10.2/21.1 L, respectively, and a mean ± s.d. AUC Although anidulafungin exposure was found comparable to that in healthy volunteers, elevated interindividual and significant interoccasion variability was found in critically ill ICU patients, which resulted in reduced PTA values in these patients.
Substances chimiques
Anti-Bacterial Agents
0
Anidulafungin
9HLM53094I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1024-1032Informations de copyright
© 2020 The British Pharmacological Society.
Références
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62(4):e1-e50. https://doi.org/10.1093/cid/civ933
Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44(6):590-598. https://doi.org/10.1177/0091270004265644
Pfizer. ECALTA summary of product characteristics. EMEA. 2009:1-14. https://www.ema.europa.eu/en/documents/product-information/ecalta-epar-product-information_en.pdf
Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of Anidulafungin. Antimicrob Agents Chemother. 2009;53(3):1149-1156. https://doi.org/10.1128/AAC.01279-08
van Wanrooy MJP, Rodgers MGG, Uges DRA, et al. Low but sufficient Anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother. 2014;58(1):304-308. https://doi.org/10.1128/AAC.01607-13
Sinnollareddy MG, Roberts JA, Lipman J, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients study. Crit Care. 2015;19(33):2-7. https://doi.org/10.1186/s13054-015-0758-3
Brüggemann RJM, Middel-Baars V, de Lange DW, et al. Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections. Antimicrob Agents Chemother. 2017;61(2):e01894-e01816. https://doi.org/10.1128/AAC.01894-16
Dupont H, Massias L, Jung B, Ammenouche N, Montravers P. Pharmacokinetic study of anidulafungin in ICU patients with intraabdominal candidiasis. J Antimicrob Chemother. 2017;72(5):1429-1432. https://doi.org/10.1093/jac/dkw568
Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Pharmacokinetics of anidulafungin in critically ill patients with Candidemia/invasive candidiasis. Antimicrob Agents Chemother. 2013;57(4):1672-1676. https://doi.org/10.1128/AAC.02139-12
Luque S, Hope W, Campillo N, et al. Population pharmacokinetics of anidulafungin in critically ill patients. Antimicrob Agents Chemother. 2019;63(7):1-5. https://doi.org/10.1128/AAC.00378-19
Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85-94. https://doi.org/10.1016/J.CMPB.2003.11.003
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS j. 2011;13(2):143-151. https://doi.org/10.1208/s12248-011-9255-z
Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54(6):2497-2506. https://doi.org/10.1128/AAC.01584-09
Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52(2):539-550. https://doi.org/10.1128/AAC.01061-07
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46(1):150-156. https://doi.org/10.1128/JCM.01901-07
Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601-607. https://doi.org/10.1093/jac/dki079
Liu P. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrob Agents Chemother. 2013;57(1):466-474. https://doi.org/10.1128/AAC.01473-12
Wasmann RE, Ter Heine R, van Dongen EP, et al. Pharmacokinetics of anidulafungin in obese and normal-weight adults. Antimicrob Agents Chemother. 2018;62(7):1-10. https://doi.org/10.1128/AAC.00063-18
Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Yeasts. In: CLSI Supplement M60. 1st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472-2482. https://doi.org/10.1056/NEJMoa066906
Kontoyiannis DP, Bassetti M, Nucci M, et al. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: analysis of pooled data from six prospective clinical studies. Mycoses. 2017;60(10):663-667. https://doi.org/10.1111/myc.12641
Arendrup M, Horn T, Frimodt-Møller N. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection. 2002;30(5):286-291. https://doi.org/10.1007/s15010-002-2131-0